Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Marqibo ® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

Susan O'Brien, M.D., Deborah A Thomas, M.D., Leonard T Heffner, M.D., Wendy Stock, M.D., Gerald L. Messerschmidt, M.D., Anne Hagey, M.D., Steven R. Deitcher, M.D., Hagop Kantarjian, M.D.

Blood (2010) 116 (21): 2143.

https://doi.org/10.1182/blood.V116.21.2143.2143

Published: 2010

Journal Articles

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

Sameer A Parikh, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Jenny Feliu, RN, Stefan Faderl, MD

Blood (2009) 114 (22): 2058.

https://doi.org/10.1182/blood.V114.22.2058.2058

Published: 2009

Journal Articles

The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All– Trans -retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Ravin Jain Garg, M.D., Hagop Kantarjian, M.D., Meetu Agrawal, M.B.B.S., Farhad Ravandi, MD, Gautam Borthakur, M.D., Steven M. Kornblau, MD, Alessandra Ferrajoli, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Jorge Cortes, MD

Blood (2009) 114 (22): 4143.

https://doi.org/10.1182/blood.V114.22.4143.4143

Published: 2009

Journal Articles

Plasma Circulating Caspase-3 Index as a Biomarker in Patients with Chronic Lymphocytic Leukemia.

Jean-Marie Bruey, Zeev Estrov, MD, Hagop Kantarjian, M.D., Susan O'Brien, M.D., Michael Keating, MD, William Wierda, Maher Albitar, M.D.

Blood (2009) 114 (22): 4381.

https://doi.org/10.1182/blood.V114.22.4381.4381

Published: 2009

Journal Articles

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Michael Rytting, M.D., Patrick Zweidler-McKay, M.D., Ph.D., Yang Hui, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D.

Blood (2008) 112 (11): 4036.

https://doi.org/10.1182/blood.V112.11.4036.4036

Published: 2008

Journal Articles

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Weigang Tong, M.D., Ph.D., Hagop Kantarjian, M.D., Susan O’Brien, M.D., Stefan Faderl, MD, Farhad Ravandi, MBBS, William G Wierda, M.D., Ph.D., Steven Kornblau, M.D., Gautam Borthakur, M.D., Guillermo Garcia-Manero, M.D., Elizabeth Burton, Mary Beth Rios, Jorge Cortes, M.D.

Blood (2008) 112 (11): 2126.

https://doi.org/10.1182/blood.V112.11.2126.2126

Published: 2008

Journal Articles

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Tefferi Ayalew, M.D., Cortes Jorge, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Animesh Pardanani, M.D., Cem Akin, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3551.

https://doi.org/10.1182/blood.V110.11.3551.3551

Published: 2007

Journal Articles

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nicholas Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1952.

https://doi.org/10.1182/blood.V110.11.1952.1952

Published: 2007

Journal Articles

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Deborah Thomas, M.D., Charles Koller, M.D., Jenny Shan, Jorge Cortes, M.D.

Blood (2007) 110 (11): 1955.

https://doi.org/10.1182/blood.V110.11.1955.1955

Published: 2007

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Jorge Cortes, M.D., Nicholas Donato, Ph.D.

Blood (2007) 110 (11): 1936.

https://doi.org/10.1182/blood.V110.11.1936.1936

Published: 2007

Journal Articles

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nick Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1938.

https://doi.org/10.1182/blood.V110.11.1938.1938

Published: 2007

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Srdan Verstovsek, MD, PhD, Ayalew Tefferi, M.D., Steven Kornblau, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Guillermo Garcia-Manero, M.D., Hagop Kantarjian, M.D.

Blood (2007) 110 (11): 3543.

https://doi.org/10.1182/blood.V110.11.3543.3543

Published: 2007

Journal Articles

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Alfonso Quintás-Cardama, MD, Ayalew Tefferi, M.D., Deborah Thomas, M.D., Jorge Cortes, M.D., Farhad Ravandi, M.D., Stefan Faderl, M.D., Guillermo Garcia-Manero, M.D., Gautam Borthakur, M.D., Neda Bell, M.D., Catriona Byrne, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D

Blood (2007) 110 (11): 3545.

https://doi.org/10.1182/blood.V110.11.3545.3545

Published: 2007

Journal Articles

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Michael Rytting, MD, Deborah Thomas, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Gautam Borthakur, M.D., William Wierda, M.D., Cesar Nunez, M.D., Steven Kornblau, M.D., Farhad Ravandi, M.D., Robert Wells, M.D., Muriera Brenda, R.N., Franklin Anna, M.D., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4342.

https://doi.org/10.1182/blood.V110.11.4342.4342

Published: 2007

Journal Articles

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Michael Rytting, MD, Deborah Thomas, M.D., Jeffrey Jorgensen, M.D., Hagop Kantarjian, M.D., Rebecca Garris, Brenda Muriera, R.N., Susan O’Brien, M.D.

Blood (2007) 110 (11): 4344.

https://doi.org/10.1182/blood.V110.11.4344.4344

Published: 2007

Journal Articles

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Farhad Ravandi, M.D., Jan Burger, M.D., Gautam Borthakur, M.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 2958.

https://doi.org/10.1182/blood.V110.11.2958.2958

Published: 2007

Journal Articles

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Tai-Sung Lee, Steven Potts, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2917.

https://doi.org/10.1182/blood.V110.11.2917.2917

Published: 2007

Journal Articles

Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Dan Jones, Ph.D., Susan O’Brien, M.D., Mary Beth Rios, Jorge Cortes, M.D.

Blood (2007) 110 (11): 2961.

https://doi.org/10.1182/blood.V110.11.2961.2961

Published: 2007

NARROW

Marqibo ® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs).

The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All– Trans -retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Plasma Circulating Caspase-3 Index as a Biomarker in Patients with Chronic Lymphocytic Leukemia.

Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.

Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib.

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.

Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.

Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL).

Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.

Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only